PMID- 24342618
OWN - NLM
STAT- MEDLINE
DCOM- 20140319
LR  - 20140127
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 443
IP  - 3
DP  - 2014 Jan 17
TI  - Laminin receptor mediates anti-inflammatory and anti-thrombogenic effects of 
      pigment epithelium-derived factor in myeloma cells.
PG  - 847-51
LID - S0006-291X(13)02129-3 [pii]
LID - 10.1016/j.bbrc.2013.12.060 [doi]
AB  - Pigment epithelium-derived factor (PEDF) has anti-inflammatory and 
      anti-thrombogenic properties both in cell culture and animal models. Although 
      adipose triglyceride lipase (ATGL) and laminin receptor (LR) are two putative 
      receptors for PEDF, which receptor mainly mediates the beneficial effects of PEDF 
      is largely unknown. In this study, we addressed the issue. siRNA raised against 
      LR (siLR) and siATGL transfection dramatically decreased LR and ATGL levels in 
      human cultured myeloma cells, respectively. Ten nM PEDF significantly reduced 
      vascular endothelial growth factor (VEGF), monocyte chemoattractant protein-1 
      (MCP-1), intercellular cell adhesion molecule-1 (ICAM-1) and plasminogen 
      activator inhibitor-1 (PAI-1) mRNA levels in siCon- or siATGL-transfected myeloma 
      cells, whereas PEDF increased rather than decreased these gene expressions in 
      siLR-transfected cells. Neutralizing antibody directed against LR (LR-Ab) or LR 
      antagonist actually bound to LR and reduced mRNA levels of VEGF, MCP-1, ICAM-1 
      and PAI-1 in myeloma cells. Further, pre-treatment of LR-Ab or LR antagonist 
      suppressed the binding of PEDF to LR and resultantly blocked the effects of PEDF 
      in myeloma cells. In addition, high concentration of LR agonist mimicked the 
      actions of PEDF on these gene expressions in myeloma cells. This study indicates 
      that PEDF causes anti-angiogenic, anti-inflammatory and anti-thrombogenic 
      reactions in myeloma cells through the interaction with LR. Target domain of LR 
      agonist and antagonist might be involved in the PEDF-signaling to gene 
      suppression in myeloma cells.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Matsui, Takanori
AU  - Matsui T
AD  - Department of Pathophysiology and Therapeutics of Diabetic Vascular 
      Complications, Kurume University School of Medicine, Kurume, Japan.
FAU - Higashimoto, Yuichiro
AU  - Higashimoto Y
AD  - Department of Chemistry, Kurume University School of Medicine, Kurume, Japan.
FAU - Yamagishi, Sho-ichi
AU  - Yamagishi S
AD  - Department of Pathophysiology and Therapeutics of Diabetic Vascular 
      Complications, Kurume University School of Medicine, Kurume, Japan. Electronic 
      address: shoichi@med.kurume-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131214
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Eye Proteins)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Receptors, Laminin)
RN  - 0 (Serpins)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (pigment epithelium-derived factor)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - EC 3.1.1.3 (Lipase)
RN  - EC 3.1.1.3 (PNPLA2 protein, human)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*metabolism
MH  - Cell Line, Tumor
MH  - Chemokine CCL2/genetics/metabolism
MH  - Eye Proteins/*metabolism/pharmacology
MH  - Fibrinolytic Agents/*metabolism
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Intercellular Adhesion Molecule-1/genetics/metabolism
MH  - Lipase/metabolism
MH  - Mice
MH  - Multiple Myeloma/*metabolism/pathology
MH  - Nerve Growth Factors/*metabolism/pharmacology
MH  - Plasminogen Activator Inhibitor 1/genetics/metabolism
MH  - RNA, Messenger/genetics/metabolism
MH  - RNA, Small Interfering/metabolism
MH  - Receptors, Laminin/antagonists & inhibitors/*metabolism
MH  - Serpins/*metabolism/pharmacology
MH  - Vascular Endothelial Growth Factor A/genetics/metabolism
OTO - NOTNLM
OT  - Inflammation
OT  - Laminin receptor
OT  - Myeloma cells
OT  - PEDF
OT  - Thrombogenesis
EDAT- 2013/12/18 06:00
MHDA- 2014/03/22 06:00
CRDT- 2013/12/18 06:00
PHST- 2013/11/27 00:00 [received]
PHST- 2013/12/10 00:00 [accepted]
PHST- 2013/12/18 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2014/03/22 06:00 [medline]
AID - S0006-291X(13)02129-3 [pii]
AID - 10.1016/j.bbrc.2013.12.060 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2014 Jan 17;443(3):847-51. doi: 
      10.1016/j.bbrc.2013.12.060. Epub 2013 Dec 14.